Theranostics 2017; 7(4):826-845. doi:10.7150/thno.17071 This issue Cite

Review

Progress of small molecular inhibitors in the development of anti-influenza virus agents

Xiaoai Wu1,2*, Xiuli Wu3,4*, Qizheng Sun2, Chunhui Zhang2, Shengyong Yang2, Lin Li1, Zhiyun Jia1✉

1. Department of Nuclear Medicine, West China Hospital, Sichuan University, Chengdu, Sichuan Province, China.
2. State Key Laboratory of Biotherapy and Cancer Center, West China Hospital, and Collaborative Innovation Center for Biotherapy, Sichuan University, Sichuan 610041, China.
3. Department of Laboratory Medicine, West China Second University Hospital, Sichuan University.
4. Key Laboratory of Birth Defects and Related Diseases of Women and Children (Sichuan University), Ministry of Education.
* These authors contributed equally to this work.

Citation:
Wu X, Wu X, Sun Q, Zhang C, Yang S, Li L, Jia Z. Progress of small molecular inhibitors in the development of anti-influenza virus agents. Theranostics 2017; 7(4):826-845. doi:10.7150/thno.17071. https://www.thno.org/v07p0826.htm
Other styles

File import instruction

Abstract

Graphic abstract

The influenza pandemic is a major threat to human health, and highly aggressive strains such as H1N1, H5N1 and H7N9 have emphasized the need for therapeutic strategies to combat these pathogens. Influenza anti-viral agents, especially active small molecular inhibitors play important roles in controlling pandemics while vaccines are developed. Currently, only a few drugs, which function as influenza neuraminidase (NA) inhibitors and M2 ion channel protein inhibitors, are approved in clinical. However, the acquired resistance against current anti-influenza drugs and the emerging mutations of influenza virus itself remain the major challenging unmet medical needs for influenza treatment. It is highly desirable to identify novel anti-influenza agents. This paper reviews the progress of small molecular inhibitors act as antiviral agents, which include hemagglutinin (HA) inhibitors, RNA-dependent RNA polymerase (RdRp) inhibitors, NA inhibitors and M2 ion channel protein inhibitors etc. Moreover, we also summarize new, recently reported potential targets and discuss strategies for the development of new anti-influenza virus drugs.

Keywords: anti-influenza virus agent, hemagglutinin inhibitors, RNA-dependent RNA polymerase inhibitors, neuraminidase inhibitors, M2 ion channel protein inhibitors.


Citation styles

APA
Wu, X., Wu, X., Sun, Q., Zhang, C., Yang, S., Li, L., Jia, Z. (2017). Progress of small molecular inhibitors in the development of anti-influenza virus agents. Theranostics, 7(4), 826-845. https://doi.org/10.7150/thno.17071.

ACS
Wu, X.; Wu, X.; Sun, Q.; Zhang, C.; Yang, S.; Li, L.; Jia, Z. Progress of small molecular inhibitors in the development of anti-influenza virus agents. Theranostics 2017, 7 (4), 826-845. DOI: 10.7150/thno.17071.

NLM
Wu X, Wu X, Sun Q, Zhang C, Yang S, Li L, Jia Z. Progress of small molecular inhibitors in the development of anti-influenza virus agents. Theranostics 2017; 7(4):826-845. doi:10.7150/thno.17071. https://www.thno.org/v07p0826.htm

CSE
Wu X, Wu X, Sun Q, Zhang C, Yang S, Li L, Jia Z. 2017. Progress of small molecular inhibitors in the development of anti-influenza virus agents. Theranostics. 7(4):826-845.

This is an open access article distributed under the terms of the Creative Commons Attribution (CC BY-NC) License. See http://ivyspring.com/terms for full terms and conditions.
Popup Image